Clinical review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.)
The objective of this review is to perform a systematic review of the beneficial and harmful effects of ixekizumab (Taltz) at the recommended dose for the treatment of adult patients with active psoriatic arthritis
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, August 2018
|
| Edition: | Version: Final (with redactions) |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this review is to perform a systematic review of the beneficial and harmful effects of ixekizumab (Taltz) at the recommended dose for the treatment of adult patients with active psoriatic arthritis |
|---|---|
| Physical Description: | 1 PDF file (111 pages) illustrations |